Mesoblast hits hurdle as FDA demands more evidence for treatment
Stem cell biotech Mesoblast’s flagship treatment has suffered a regulatory setback after the US Food and Drug Administration (FDA) demanded further evidence of its effectiveness before granting approval.
The new demand comes despite the regulator’s advisory committee voting in August that the data provided by Mesoblast supported the efficacy off its remestemcel-L treatment. The company, investors and analysts had subsequently expressed significant confidence that the product would be approved for use against acute graft-versus-host disease in children, a severe immune reaction that occurs in children after a bone marrow transplant.
However, the “complete response letter” by the FDA, which outlines the additional steps Mesoblast must take before approval, has cast fresh doubts over the future of Mesoblast’s treatment. Under the new FDA recommendations, Mesoblast may need to conduct one additional randomised trial of remestemcel-L in adults or children to prove its efficacy.
Mesoblast’s shares, which went into a trading halt on Thursday in anticipation of the regulatory ruling, opened 44 per cent weaker at $2.87 on the back of the news.
The biotech, valued at $1.9 billion, has been striving for a decade to get remestemcel-L approved in the US market. It is also trialling the same product for treatment of coronavirus, in cases where patients are experiencing severe respiratory distress.
The prospect of the coronavirus treatment has sent shares rallying in recent months. In April, Mesoblast shares were sitting at $1.46 but were at $5.08 before going into the trading halt this week.
Chief executive Silviu Itescu said he believed the request for more data would set the company’s planned launch of the product back “somewhere in the order of 3 to 5 months”.
“It would have been great if they had simply took the advice of their panel and given immediate unrestricted approval. Short of that, this is the way these things evolve,” he said.
The company said it would ask the US regulator for a ‘Type A’ meeting, to discuss whether it can have an accelerated approval process with the condition of a post-approval study. If this meeting is scheduled it would occur in 30 days.
Last month, the FDA’s advisory committee ran the ruler over data about remestemcel-L’s effectiveness and ultimately voted in favour of the treatment, nine to one. However, the expert panel did discuss whether the company’s trial of the product in children provided enough evidence because it did not include a control group.
Mr Silviu said physicians are typically reluctant to enrol children in randomised studies of trial drugs.
“It’s really not feasible to do a randomised control study in children,” he said.
He added that Mesoblast will be looking at further research options for remestemcel-L in adult populations, but not another trial for paediatric patients.
When asked about the market’s reaction to the news, he said he was not focused on the share price.
“It doesn’t matter. We’re marching forward – and there is no question on safety here.”
Market Recap
A concise wrap of the day on the markets, breaking business news and expert opinion delivered to your inbox each afternoon. Sign up for the Herald‘s here and The Age‘s here.
Emma reports on healthcare companies for The Age and Sydney Morning Herald. She is based in Melbourne.
Most Viewed in Business
Source: Thanks smh.com